Evidence shows that anti-VEGF agents possess a variety of in vivo mechanisms of action comprising early effects of the regression of existing tumor microvasculature and normalization of remaining tumor vasculature, as well as continued effects such as inhibition of new tumor vasculature. This evidence concerns the gene VEGFA and neoplasm.